CMS proposes expanded Medicare Advantage audits, sparking double‑digit sell‑off in UnitedHealth and peers
The Centers for Medicare & Medicaid Services released the “CRUSH” proposal on Nov. 16, expanding Medicare Advantage risk‑adjustment audits and allowing recoveries back to 2018. UnitedHealth Group’s shares fell between 9% and 12% over the next two days, closing around $350, while Humana, CVS Health, Cigna and Elevance also dropped double‑digits. Analysts note the rule could force roughly $9 billion of annual clawbacks from insurers, raising concerns about earnings and cash flow.
Why it matters
The potential $9 billion per year in Medicare Advantage recoveries could compress UnitedHealth’s adjusted earnings and increase cash‑outflows, prompting investors to reassess valuation multiples (the company trades at about 17‑18 × forward earnings) and dividend sustainability. Analysts such as Oppenheimer warn that legal challenges may delay implementation, but the immediate market impact reflects heightened regulatory risk.
Key facts
- 1CMS announced the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) rule on Nov. 16, proposing to apply audit findings to contracts starting with payment year 2018. quantisnow.com
- 2The rule estimates recoveries of roughly $9 billion per payment year in Medicare Advantage overpayments. quantisnow.com
- 3UnitedHealth shares fell 9.01% to $354.58 at 1:40 p.m. ET on Nov. 18, 2026. quantisnow.com
- 4Humana fell 10.55% to $396.57 at the same time, while Elevance dropped 6.47% to $405.88. quantisnow.com
- 5UnitedHealth’s price was $349.81 after a 10.2% decline reported on Nov. 18. beinsure.com
- 6Analysts estimate the CRUSH proposal could save nearly $90 billion over ten years, with $9 billion per year from Medicare Advantage audits. beinsure.com
Open questions
- Share‑price decline percentages differ across sources (4.62% on Nov. 17 vs 9‑12% on Nov. 18).
Summary written by AlphAI AI Desk from 17 of 17 sources. Not investment advice. Figures are as stated by the linked sources.